These Biotech Companies Are Prime For a Breakout as the Market for Smoking Cessation Products Heats Up

The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a number of biotechs that are primed for a breakout as the market for smoking cessation products heats up.

Companies included: 22nd Century Group (XXII), Arena Pharamceuticals (ARNA), Gilla Inc (OTCMKTS: GLLA), Imperial Brands Plc (OTC: IMBBF)

According to a research report from Mintel, the United States smoking cessation market already exceeds $1 billion. Because an ever-increasing number of Americans are seeking effective ways to kick their nicotine habit, by 2017 smoking cessation products sales in the US are projected to top $1.2 billion and worldwide sales exceeding $3 billion. This should hardly come as a surprise as governments are tightening their smoking regulations, and more and more smokers are becoming aware of the long-term health effects of smoking.

For investors looking for a chance to cash in on the smoking cessation opportunity while it is still largely under the radar, 22nd Century Group (NYSE MKTS: XXII) is one company that should be carefully considered. This plant-based biotechnology company has come up with a revolutionary way of aiding smokers in their quest for a nicotine free lifestyle using the Company’s proprietary genetic engineering and plant breeding technology. With more than 200 patents in 96 countries controlling the genes in the tobacco plant responsible for nicotine production, 22nd Century is the only company in the world able to significantly increase or decrease the level of nicotine in naturally growing tobacco plants.

Low nicotine cigarettes encourage smokers to quit

From this technology, 22nd Century Group has developed both low and high nicotine cigarettes; these products are marketed under the ‘MAGIC’ and ‘RED SUN’ brand names respectively. It is important to note that the company’s Very Low Nicotine (VLN) smoking cessation cigarettes, code-named “X-22,” contain 20x less nicotine than conventional cigarettes (95% less nicotine than regular cigarettes made by traditional “Big Tobacco” companies). In fact, as a result of the Company’s monopoly on the genetic pathway in the tobacco plant responsible for nicotine production, 22nd Century is the only company in the world capable of producing combustible cigarettes containing naturally grown tobacco with non-addictive levels of nicotine.

In order to clearly appreciate the massive potential of these cigarettes, note that an independent clinical study – actually funded directly by the FDA last year – found that smokers who used 22nd Century’s proprietary Very Low Nicotine cigarettes went on to smoke fewer cigarettes per day and significantly increased quit rates. The withdrawal symptoms were also minimal signaling that lower nicotine intake could indeed prove far more effective to helping people stop smoking. The company is currently pursuing regulatory approval from the FDA to market X-22 as a prescription smoking cessation aid. When the Company announces the start of its Phase III trials, the high-visibility milestone could provide enough momentum for the Company’s stock to reach all-time highs (in excess of $6).

Modified risk cigarettes status will drive valuation

Apart from the huge opportunity in smoking cessation, 22nd Century Group also has another catalyst that will, without a doubt, play a significant role in increasing shareholder value. Like X-22, the company’s BRAND A Very Low Nicotine over-the-counter cigarettes contain approximately 95 percent less nicotine than conventional tobacco cigarettes, while 22nd Century’s BRAND B boasts of an extremely low “tar-to-nicotine” ratio. With these specifications, the company is seeking regulatory approval in the U.S. to marketBRAND A and BRAND B as FDA authorized ‘reduced exposure’ or Modified Risk Tobacco Products (MRTP’s). To date, no other company has been authorized by the FDA to label and market tobacco products as Modified Risk. 22nd Century intends to be the first company in the world to win this important designation which could generate hundreds of millions of dollars in near-term licensing and product sales revenue.

Considering that the FDA has put in place regulations that prohibit the sale of all tobacco products with implied health claims or even with package labels that include the terms ‘light,’ or ‘ultra-light,’ or ‘low tar,’ 22nd Century’s Brand A FDA- authorized Modified Risk Tobacco Products labeling (which is expected this year) will be a major development to watch out for. According to research from the National Cancer Institute (NCI), before FDA banned the ‘light’ label, ‘light’ cigarettes commanded an impressive 83.5 percent of the tobacco market in 2005. This fact suggests that when 22nd Century group’s BRAND A is authorized by the FDA to actually be labeled and marketed as a reduced exposure tobacco product, the brand has the potential to capture a very lucrative piece of the $70 billion US cigarette market.

More companies to put on the watchlist

Arena Pharamceuticals (ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. The company recently developed Lorcaserin, an investigational product for smoking cessation that shows plenty of promise going forward. Lorcaserin is a serotonin 2C receptor agonist which has demonstrated statistically significant improvement in reducing the number of patients who smoke after 12 weeks of treatment.

According to Aena’s CEO Jack Lief, the proof-of-concept trial provided what the company believes is the first clinical evidence that a selective serotonin 2C agonist may have a treatment effect for smoking cessation. The pre-clinical data suggest that Lorcaserin which selectively activates serotonin 2C receptors in the brain, may modulate the mesolimbic dopaminergic reward system helping smokers in their quite attempts.


Gilla Inc (OTCMKTS: GLLA) is a manufacturer, marketer and distributor of generic and premium branded e-liquid used in vaporizers, e-cigarettes, and other vaping hardware and accessories in Europe, Canada, and the U.S. While this company does not have a specific product tailored to help smokers quit, it does present a unique opportunity in the space that investors should consider. As mentioned earlier on, more smokers are looking for less harmful ways of getting their nicotine fix as they struggle to quit entirely which is where Gilla comes in. More smokers are turning to e-cigarettes and e-liquids for vaporizers to help them quit with the potential market rising to over $3 billion.


Imperial Brands Plc (OTC: IMBBF) is a well-known multinational tobacco company which has shown remarkable resilience in the face of a declining smoking population with the stock gaining 4 percent on an YTD basis. The company has solid growth prospects even as the tobacco industry comes under increasing government regulation with good reason. Imperial Brands is well exposed to the opportunity in reduced risk products with its e-cigarettes and with its massive financial power has the ability to acquire new innovative companies developing reduced risk tobacco products.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.


To receive text Message alerts when new articles are released click here:
Follow us on Twitter: @Wealthy_VC
Like us on Facebook:


This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader’s parent company has been compensated fifteen thousand dollars per month for a 12 month contract by 22nd Century Group. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

pour la musculation tamoxifen buylivraison anonyme, prix favorable As a rule, the infection occurs during penetrative sexual intercourse buy metronidazole no prescription moist environment and can remain viable. cialis 20mg rezeptfreider Wirkstoff des Arzneimittels wird nicht verlassen, Zweifel an der Wirksamkeit der Pillen ein bewährtes Medikament zur Behandlung von BPH in einer Dosierung von 10 mg, die Möglichkeit gibt, ein neues Potential des Penis, um zu versuchen buy Retin AThis drug will no doubt help to solve the problem with acne in young people from 16 years, thanks to the active ingredient of this cream you will experience relief, people will stop laughing at you Diagnosticare la causa della disfunzione erettilecomprar cilaiscosì spesso il trattamento può comportare molteplici tecniche. Comprar cialis en línea

Wealthy Venture Capitalist